46232 Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices 

Dated: August 28, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–21522 Filed 9–4–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to Section 1301.33(a) of Title 

21 of the Code of Federal Regulations 

(CFR), this is notice that on June 26, 

2009, Noramco Inc., Division of OrthoMcNeil, Inc., 500 Swedes Landing Road, 

Wilmington, Delaware 19801–4417, 

made application by letter to the Drug 

Enforcement Administration (DEA) for 

registration as a bulk manufacturer of 

Noroxymorphone (9668), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to bulk 

manufacture the listed controlled 

substance as a reference standard for 

distribution to its customers which are 

analytical laboratories. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such a substance, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, VA 22152; and must be 

filed no later than November 9, 2009. 

Dated: August 28, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–21524 Filed 9–4–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a) of Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on March 18, 2009, 

Research Triangle Institute, Kenneth H. 

Davis Jr., Hermann Building, East 

Institute Drive, P.O. Box 12194, 

Research Triangle, North Carolina 

27709, made application by renewal to 

the Drug Enforcement Administration 

(DEA) as a bulk manufacturer of the 

basic classes of controlled substances 

listed in schedules I and II: 

Drug Schedule 

Marihuana (7360) ......................... I 

Tetrahydrocannabinols (7370) ..... I 

Cocaine (9041) ............................. II 

The Institute will manufacture small 

quantities of cocaine and marihuana 

derivatives for use by their customers in 

analytical kits, reagents, and reference 

standards as directed by the National 

Institute on Drug Abuse. 

Any other such applicant, and any 

person who is presently registered with 

DEA to manufacture such substances, 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such written comments or 

objections should be addressed, in 

quintuplicate, to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than November 9, 2009. 

Dated: August 21, 2009. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. E9–21526 Filed 9–4–09; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Manufacturer of Controlled 

Substances; Notice of Application 

Pursuant to § 1301.33(a), Title 21 of 

the Code of Federal Regulations (CFR), 

this is notice that on July 1, 2009, 

Alltech Associates Inc., 2051 Waukegan 

Road, Deerfield, Illinois 60015, made 

application by renewal to the Drug 

Enforcement Administration (DEA) to 

be registered as a bulk manufacturer of 

the basic classes of controlled 

substances listed in schedules I and II: 

Drug Schedule 

Methcathinone (1237) .................. I 

N-Ethylamphetamine (1475) ........ I 

N,N-Dimethylamphetamine (1480) I 

4-Methylaminorex (cis isomer) 

(1590).

I 

Alpha-ethyltryptamine (7249) ....... I 

Lysergic acid diethylamide (7315) I 

2,5-Dimethoxy-4-(n)- 

propylthiophenethylamine 

(7348).

I 

Drug Schedule 

Tetrahydrocannabinols (7370) ..... I 

Mescaline (7381) .......................... I 

4-Bromo-2,5- 

dimethoxyamphetamine (7391).

I 

4-Bromo-2,5- 

dimethoxyphenethylamine 

(7392).

I 

4-Methyl-2,5- 

dimethoxyamphetamine (7395).

I 

2,5-Dimethoxyamphetamine 

(7396).

I 

2,5-Dimethoxy-4- 

ethylamphetamine (7399).

I 

3,4-Methylenedioxyamphetamine 

(7400).

I 

N-Hydroxy-3,4- 

methylenedioxyamphetamine 

(7402).

I 

3,4-Methylenedioxy-Nethylamphetamine (7404).I 

3,4- 

Methylenedioxymethamphetamine (MDMA) (7405).

I 

4-Methoxyamphetamine (7411) ... I 

Alpha-methyltryptamine (7432) .... I 

Bufotenine (7433) ......................... I 

Diethyltryptamine (7434) .............. I 

Dimethyltryptamine (7435) ........... I 

Psilocybin (7437) .......................... I 

Psilocyn (7438) ............................. I 

5-Methoxy-N,Ndiisopropyltryptamine (7439).I 

N-Ethyl-1-phenylcyclohexylamine 

(7455).

I 

1-(1-Phenylcyclohexyl)pyrrolidine 

(7458).

I 

1-Phenylcyclohexylamine (7460) I 

1-[1-(2- 

Thienyl)cyclohexyl]piperidine 

(7470).

I 

Normorphine (9313) ..................... I 

Methamphetamine (1105) ............ II 

Phencyclidine (7471) .................... II 

Phenylacetone (8501) .................. II 

1- 

Piperidinocyclohexanecarbonitrile (8603).

II 

Cocaine (9041) ............................. II 

Codeine (9050) ............................. II 

Dihydrocodeine (9120) ................. II 

Dihydromorphine (9145) ............... II 

Ecgonine (9180) ........................... II 

Meperidine intermediate-B (9233) II 

Noroxymorphone (9668) .............. II 

The company plans to manufacture 

high purity drug standards used for 

analytical application only in clinical, 

toxicological, and forensic laboratories. 

Any other such applicant and any 

person who is presently registered with 

DEA to manufacture such substances 

may file comments or objections to the 

issuance of the proposed registration 

pursuant to 21 CFR 1301.33(a). 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 


jlentini on DSKJ8SOYB1PROD with NOTICES